Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 12, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	154,518	59,956	69,333	51,403	70,547	115,098
Market Cap Growth	195.69%	-13.53%	34.88%	-27.14%	-38.71%	243.36%
Enterprise Value	147,767	54,283	63,850	44,899	59,352	109,367
Last Close Price	89.05	36.60	42.75	33.50	48.25	82.05
PS Ratio	12.34	5.98	10.14	9.98	13.46	25.21
PB Ratio	9.78	4.30	5.02	4.24	5.56	11.04
P/TBV Ratio	10.82	4.40	5.04	4.25	5.57	11.04
P/FCF Ratio	97.40	175.32	-	-	-	-
P/OCF Ratio	77.63	43.78	425.78	-	-	-
EV/Sales Ratio	11.81	5.41	9.34	8.72	11.33	23.96
EV/EBITDA Ratio	106.67	2126.28	-	-	-	-
EV/FCF Ratio	93.15	158.73	-	-	-	-
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14
Debt / EBITDA Ratio	2.54	50.93	-	-	-	-
Debt / FCF Ratio	2.33	8.81	-	-	-	-
Net Debt / Equity Ratio	-0.43	-0.38	-0.59	-0.55	-0.63	-0.79
Net Debt / EBITDA Ratio	-4.73	-210.62	5.70	2.06	2.57	14.13
Net Debt / FCF Ratio	-4.26	-15.72	7.56	2.11	2.11	8.68
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40
Inventory Turnover	2.94	2.69	1.51	1.00	1.19	1.45
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%
Return on Assets (ROA)	2.65%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%
Return on Capital Employed (ROCE)	5.00%	-1.60%	-9.70%	-22.20%	-20.50%	-5.40%
Earnings Yield	0.80%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%
FCF Yield	1.03%	0.57%	-1.54%	-6.19%	-5.38%	-0.82%
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.